CALOX

repaid

This transaction consists of a long-term corporate loan of up to US$14 million to Calox de Costa Rica S.A. ("CALOX" or the "Company"). CALOX is a company that has operated for more than 25 years in Central America and the Caribbean, dedicated to the production, distribution, and sale of mainly generic pharmaceutical products.The proposed financing includes two main objectives: the first consists of the acquisition of the current plant to make improvements in infrastructure and energy efficiency, which will allow it to become certified and expand its production capacity in the medium term; the second objective consists of providing medium-term financing for permanent working capital, to enhance: (i) the expansion of medicines under its own brand ("Xaikus"); (ii) the expansion into the South American market; and (iii) continuing research and development of new products, as well as strengthening its presence in the Central American market with drugs attending to the health crisis caused by the COVID-19 pandemic.